A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

This study is testing an all-oral combination of three cancer drugs — a menin inhibitor (SNDX-5613), a hypomethylating agent (decitabine/cedazuridine), and venetoclax — for people with acute myeloid leukemia (AML) or related blood cancers that have specific genetic features. **You may be eligible if...** - You are at least 12 years old and weigh at least 40 kg - You have been newly diagnosed with AML or a related blood cancer and are not eligible for intensive chemotherapy, OR your cancer has returned or stopped responding to prior treatment - Your cancer has a specific genetic mutation (KMT2A, NUP98, or NPM1) - Your white blood cell count is below 25,000 at enrollment (cytoreduction is allowed beforehand) - Your heart function and liver function are within acceptable ranges **You may NOT be eligible if...** - You have a type of leukemia called acute promyelocytic leukemia - You have active, uncontrolled infection - You are pregnant or breastfeeding - You have significant heart or liver problems Talk to your doctor to see if this trial is right for you.